NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Feb 8, 2010 - Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) biotechnology company, will present at the 12th Annual BIO CEO & Investor Conference tomorrow, Tuesday, February 9, 2010 at 3:00 PM EST.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 8, 2010 - Biogen Idec , a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced that John R. Richert, M.D., will be joining the Company as a Senior Fellow in Neurology Research and Development and Nancy D. Richert, M.D., Ph.D., will be joining as a Fellow in Neurology Research and Development.
THE WOODLANDS, Texas--(BUSINESS WIRE)--Feb 8, 2010 - Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that the Company, as requested by the FDA during the Type C meeting held on January 25, 2010, has sent a revised indication statement to the FDA's Division of Reproductive and Urologic Products for the use of Androxal® in the treatment of men wishing to preserve fertility while being treated for their hypogonadal state.
MENLO PARK, Calif.--(BUSINESS WIRE)--Feb 8, 2010 - Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company's product development programs at 10:30 a.m. EST on Tuesday, February 9, 2010, at the 12th Annual BIO CEO & Investor Conference in New York City.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 8, 2010 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the “Soutschek and Manoharan” patent (Application No. 10/916,185), which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery.
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Feb 8, 2010 - Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.
JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Feb 8, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that they have amended the marketing and distribution agreement for oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS).
NESS ZIONA, Israel--(BUSINESS WIRE)--Feb 8, 2010 - Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.
HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Feb 8, 2010 - Amneal Pharmaceuticals is pleased to announce that it received U.S. FDA approval to manufacture combination Tramadol HCl in 37.5 mg strength and Acetaminophen in 325 mg strength (Tramadol/APAP) in tablet form effective December 9, 2009.
HAYWARD, Calif., Feb. 8 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
(BUSINESS WIRE)--Feb 8, 2010 - Amendola Communications Jodi Amendola, CEO of Amendola Communications, is an award-winning public relations and marketing communications expert with two decades of experience in implementing and overseeing strategic marketing and public relations programs for healthcare information technology (HIT) companies.
AMSTERDAM--(BUSINESS WIRE)--Feb 8, 2010 - AMT is a leader in the field of gene therapy. Its first product is in registration in EU for Lipoprotein Lipase Deficiency, an orphan condition. AMT's other development programmes include: Hemophilia, Parkinson's Disease, Duchenne and Porphyria. AMT's gene therapy approach offers a safe, long-term (potentially lifetime) therapy from a single treatment. This could fundamentally alter treatment approaches in target indications.
USINESS WIRE)--Feb 8, 2010 - UBS The UBS Global Healthcare Services Conference will feature presentations and updates from senior management from more than 120 of the leading healthcare services firms around the world, companies that continue to shape this dynamic field. Participants from acute care, alternate site, distribution, healthcare REITs, information technology, laboratory services, long-term care, managed care, pharmaceutical services, staffing and other healthcare service sectors will attend, including:
(BUSINESS WIRE)--Feb 8, 2010 - BioNJ The feature film “Extraordinary Measures” is inspired by the true story of Amicus President and CEO John Crowley, who bucked conventional wisdom and risked his family's fortune to pursue a cure for his children's life-threatening disease.
ALBANY, N.Y.--(BUSINESS WIRE)--Feb 8, 2010 - AMRI (NASDAQ: AMRI) today reported financial and operating results for the fourth quarter and full year ending December 31, 2009.
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Feb 8, 2010 - Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced today that it has named David Soergel, M.D. vice president and head, clinical development. In this role, Dr. Soergel is responsible for shaping Trevena's clinical strategy and the operational execution of its development programs.
NEW YORK--(BUSINESS WIRE)--Feb 8, 2010 - The 20th Annual UBS Global Healthcare Services Conference opens today at the Grand Hyatt in New York City and runs through Wednesday, February 10th. The conference will feature presentations and updates from senior management from more than 120 of the leading healthcare services firms around the world, companies that continue to shape this dynamic field. Presenting companies include:
CARY, N.C.--(BUSINESS WIRE)--Feb 8, 2010 - Industry Standard Research (ISR Reports) today announced the launch of a substantial research report titled Success in Patient and Investigator Recruitment. This report presents data and analysis from 362 interviews with Patients, Principal Investigators, and Drug development professionals from around the world.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Feb 8, 2010 - Quintiles, the world's leading biopharmaceutical services company, has again been named to Training magazine's “Training Top 125,” the publication's annual report that ranks companies based on their employer-sponsored training and development programs.
BETHESDA, Md.--(BUSINESS WIRE)--Feb 8, 2010 - REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers have correlated Tβ4 levels with the clinical course of patients with hepatitis B virus-related liver failure. It was reported that serum thymosin β4 levels were significantly lower in patients with chronic hepatitis B infection and that the magnitude of the reduction of thymosin β4 was closely related to the severity of the hepatic injury and to patient death. Since patients with higher Tβ4 levels survived the disease, changes in Tβ4 values could reflect outcome in some liver failure patients.
|
